We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Introgen Wins Decision Against Schering-Plough At European Patent Office

Law360 (June 3, 2005, 12:00 AM EDT) -- Introgen Therapeutics Inc. said it won a patent battle with Schering-Plough Corp. that clears the path for commercialization of its Advexin cancer treatment in Europe.

The biopharmaceutical company said it won the decision on its opposition of European Patent 0-390-323 before the European Patent Office.

Introgen said all claims directed to therapeutic applications of the p53 gene, the active component of the company's Advexin molecular therapy, were revoked by the EPO's technical board of appeals.

The patent, entitled Detection of Loss of the Wild-Type p53 Gene,...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.